Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights
  • Choose License Type

Global Relapsed or Refractory Diffuse Large B-cell Lymphoma Market, By Drug Type (Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta, and Others), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 1,364 million in 2021 and is expected to exhibit a CAGR of 4.2% over the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.

Market Players and research institutes are focusing on developing treatments for relapsed or refractory diffuse large B-cell lymphoma by initiating clinical trials. The details of clinical trials are given in the table below

ClinicalTrials.gov Identifier Sponsor Study Details Study Start Date Estimated Study Completion Date
NCT04442022 Karyopharm Therapeutics Inc. A Phase 2/3 study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL) September 3, 2020 August 2024
NCT04436107 BeiGene A Phase 1 Dose Escalation and Expansion Study of Bruton Tyrosine Kinase (BTK) Inhibitor, Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma September 11, 2020 February 28, 2023
NCT03992339 Antengene Corporation A phase 2 study of ATG-010 in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) April 9, 2020 December 2021
NCT04408638 Hoffmann-La Roche A phase 3 study to evaluate the Efficacy and Safety of Glofitamab in Combination With Gemcitabine Plus Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma February 23, 2021 March 1, 2022
NCT03719989 Seoul National University Hospital A phase 2 of Epigenetic Priming Using Azacitidine Followed by Rituximab-GDP Immunochemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma December 1, 2018 November 30, 2023
NCT04665765 City of Hope Medical Center A phase 2 study of Polatuzumab Vedotin With Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for Relapsed/Refractory Diffuse Large B-cell Lymphoma January 18, 2021 December 31, 2023

Global Relapsed or Refractory Diffuse Large B-cell Lymphoma Market – Impact of Coronavirus (Covid-19) Pandemic

Healthcare providers are adopting telehealth solutions to conduct their services for cancer patients while maintaining social distancing to tackle the COVID-19 pandemic without compromising patients’ health. For instance, patients can arrange virtual appointments with their doctors for consultations. Healthcare providers are also taking the following measures to reduce the spread of the COVID-19 infection:

  • Hospitals have restricted entry of visitors and only emergency cases are handled.
  • A screening for possible symptoms of COVID-19 is being performed for all the individuals entering the hospitals.
  • Healthcare givers are encouraging patients to conduct patients’ scheduled appointments via telemedicine platforms.

Browse 36 Market Data Tables and 35 Figures spread through 155 Pages and in-depth TOC on “Relapsed or Refractory Diffuse Large B-cell Lymphoma Market”- Global Forecast to 2028, By Drug Type (Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta, and Others), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).

To know the latest trends and insights prevalent in the global relapsed or refractory diffuse large b-cell lymphoma market, click the link below:

https://www.coherentmarketinsights.com/market-insight/relapsed-or-refractory-diffuse-large-b-cell-lymphoma-market-4426

Key Takeaways of the Global Relapsed or Refractory Diffuse Large B-cell Lymphoma Market:

  • The global relapsed or refractory diffuse large B-cell lymphoma market is expected to exhibit a CAGR of 4.2% over the forecast period, owing to increasing agreements by market players. For instance, in April 2019, Forty Seven Inc., a clinical-stage company, extended its agreement with Genentech, a subsidiary of F. Hoffmann-La Roche AG, to initiate a third clinical trial, evaluating Forty Seven’s CD47 antibody 5F9 in combination with Genentech’s Rituxan, anti-CD20 antibody rituximab and Tecentriq, an anti-PDL1 antibody, atezolizumab, in patients with diffuse large B-cell lymphoma (DLBCL)
  • Among drug type, XPOVIO segment accounted for the largest market share in 2020, owing to increasing approvals by regulatory authorities. In June 2020, the U.S. Food and Drug Administration approved XPOVIO (selinexor) by Karyopharm Therapeutics, for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
  • Key players operating in the global relapsed or refractory diffuse large B-cell lymphoma market include MorphoSys US Inc., Bristol Myers Squibb, Karyopharm Therapeutics, F. Hoffmann-La Roche AG, Merck & Co., Inc., Gilead Sciences, Inc., and Novartis AG
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner